Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2014-12-11

Clinical Trial Update: Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial exploring rosuvastatin to induce resolution of severe preeclampsia up to 48 hours after delivery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Soroka University Medical Center | Conditions: Severe Pre-eclampsia | Phase 1, Phase 2 | Status: UNKNOWN